Further analysis revealed that TDRKH-AS1 was predominantly expressed in the cytoplasm of BC cells, and functioned as a competitive endogenous RNA (ceRNA) for miR-134-5p, thereby reducing the inhibitory effects of miR-134-5p on its target gene cAMP response element-binding protein 1 (CREB1). Here, TDRKH is linked to breast cancer.